Archive for September, 2009
28 2009
Cyanotech Announces 5 New Condition-Specific Formulas with Astaxanthin
Cyanotech’s Medical Director Robert Corish, MD has now formulated five condition-specific recipes featuring BioAstin® Natural Astaxanthin as the “star” of each. There are many areas of medical research on Astaxanthin, which led Dr. Corish to combine BioAstin with the best, industry-leading nutrients for each condition in efficacious dosages.
BioAstin’s benefits derive from its superior antioxidant activity and from its ability to support and maintain natural inflammatory response, enhancing skin, muscle and joint health. Cyanotech produces these products from microalgae grown at its 90-acre facility in Hawaii using patented and proprietary technology and distributes them to nutritional supplement, nutraceutical and cosmeceutical makers and marketers in more than 40 countries worldwide.
26 2009
New Issue of Marine Drugs Available
The release of following issue: Mar. Drugs, Volume 7, Issue 3 (September 2009), Pages 268-482 is available at
http://www.mdpi.com/1660-3397/7/3/
Marine Drugs (ISSN 1660-3397, CODEN: MDARE6) is an open access journal on the research, development and production of drugs from the sea, including marine natural product chemistry. Published online quarterly.
14 2009
Troublesome green algae serve as coating substrate in record-setting battery
Unwanted blooms of Cladophora algae throughout the Baltic and in other parts of the world are not entirely without a positive side. A group of researchers at the Ångström Laboratory at Uppsala University have discovered that the distinctive cellulose nanostructure of these algae can serve as an effective coating substrate for use in environmentally friendly batteries. The findings have been published in an article in Nano Letters.
14 2009
Glycomar receives funding to bring products to nutrition and cosmetics market
An Argyll biotechnology company has been awarded funding from Highlands and Islands Enterprise (HIE) to help launch a number of its products for the commercial market.
Glycomar Ltd, based at Dunstaffnage near Oban, is looking to bring products to market in the fields of both nutrition and cosmetics.
The business has been awarded up to £55,850 towards setting up an 18 month development programme that will build on the success of its research and development of the last three years. The potential products use anti-inflammatory agents to improve joint health and intestinal health and in skin care to promote anti-aging. The development programme will complete the R&D process and bring two new products to market.
11 2009
UK Networking Meeting on Development of Algal Products and Processes
Biofuels East and the InCrops Enterprise Hub are organising a series of regional meetings to lever out the East of England capabilities in algae technologies. The first meeting will be hosted at the University of East Anglia on 15th October 2009.
The event will address the opportunities and challenges in high value applications, bioremediation and bioenergy, with special emphasis on funding opportunities. It will bring together industry and academia from renewables sectors to accelerate innovation and technology transfer.
10 2009
Norway establishes new strategy for marine bioprospecting
Minister of Fisheries and Coastal Affairs Helga Pedersen and State Secretary in the Ministry of Trade and Industry Rikke Lind recently presented the government’s national strategy for marine bioprospecting.
“Marine bioprospecting is a strategic focus area in which Norway has positive potential for asserting itself in international competition. The government’s aim is to unlock the great potential for wealth creation which lies within marine bioprospecting,” said State Secretary Rikke Lind of the Ministry of Trade and Industry.
09 2009
Powerful fish-killing toxin could have cancer-killing properties
A powerful fish-killing toxin could have cancer-killing properties as well, according to collaborative research led by Agricultural Research Service(ARS) microbiologist Paul V. Zimba and chemist Peter Moeller of the U.S. National Oceanic and Atmospheric Administration (NOAA). The toxin, called euglenophycin, has a molecular structure similar to that of solenopsin, an alkaloid from fire ant venom known to inhibit tumor development.
The findings were published online in July in the journal Toxicon.
02 2009
Aker BioMarine to be exclusive supplier of company’s Superba™ Krill Oil to Schiff Nutrition International
The biotechnology company Aker BioMarine has signed an agreement to be the exclusive supplier of the company’s Superba™ Krill Oil dietary supplement to the market leader Schiff Nutrition International. The agreement is a major breakthrough for Aker BioMarine in the US market.
RSS Feed 
Search
News Archive
Categories
Sponsors
Latest News
- Norwegian Omega-3 oil from Calamari hits the market
- Marine ingredient-based liquid fertilizers promoted for helping plants fight drought in Philippines
- Clay-algal extract combination has use in antibiotec-free animal feed and purification of water from waste effluents
- Marine Ingredient Entrepreneur Talking Up Seaweed and Nova Scotia at the Olympics
- International Seaweed Symposium to be held in Ensenada Baja California México, February 22-26, 2010
Recent Comments
- Kristina on Bodega Algae and Bigelow Lab land SBIR grant
- Research shows effectiveness of natural seaweed extract on … | Health News on Research shows effectiveness of natural seaweed extract on Osteoarthritis symptoms
- Aquapreneur - Research shows effectiveness of natural seaweed … | Health News on Research shows effectiveness of natural seaweed extract on Osteoarthritis symptoms
- Dr Mark G J Hartl on National Seminar on Marine Biotechnology- SEMBIOT ‘10, India
- Ольга on UK’s marine science sector flourishing
Share Aquapreneur
